Hemofiltration for cytokine-driven illnesses: The mediator delivery hypothesis

International Journal of Artificial Organs

Volumn 28, Issue 8, 2005, Pages 777-786

  Di Carlo, Joseph V ^a   Alexander, S R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cytokine; Hemofiltration; Lymphatics; Physiology; Sepsis; Ultrafiltration

Indexed keywords

BYPRODUCTS;

CYTOKINES; HEMOFILTRATION; IMMUNE RESPONSE; INFLAMMATORY MEDIATORS; LYMPHATIC; RENAL FAILURE; RENAL FUNCTIONS; SEMI-PERMEABLE MEMBRANES; SEPSIS; SYSTEMIC INFLAMMATION;

ULTRAFILTRATION;

CHEMOKINE; CYTOKINE; DNA; GAMMA INTERFERON; HYALURONIC ACID; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CRITICAL ILLNESS; CRYSTALLOID; DIFFUSION; ERYTHROCYTE; HEMOFILTRATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFUSION; INTERSTITIUM; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER; LYMPH FLOW; METABOLISM; RETICULOENDOTHELIAL SYSTEM; REVIEW; SEPSIS;

EID: 27544495456     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800803     Document Type: Review

References (56)

1. Ronco C, Ballestri M, Cappelli G. Dialysis membranes in convective treatments. Nephrol Dial Transplant 2000; 15 (suppl 2): S31-6.
2. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-53.
3. Gohl H, Buck R, Strathmann H. Basic features of the polyamide membranes. Contrib Nephrol 1992; 96: 1-25.
4. Bellomo R, Tipping P, Boyce N. Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Ren Fail 1995; 17: 457-66.
5. Heering P, Morgera S, Schmitz FJ, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23: 288-96.
6. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C. Cytokine removal during continuous renal replacement therapy: An ex vivo comparison of convection and diffusion. Int J Artif Organs 2004; 27: 388-97.
7. Uchino S, Bellomo R, Goldsmith D, et al. Cytokine removal with a large pore cellulose triacetate filter: An ex vivo study. Int J Artif Organs 2002; 25: 27-32.
8. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: The peak concentration hypothesis. Artif Organs 2003; 27: 792-801.
9. Di Carlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol 2003; 25:801-5.
10. Asachenkov AL, Marchuk GI, Mohler RR, Zuev SM. Immunology and disease control: A systems approach. IEEE Trans Biomed Eng 1994; 41: 943-53.
11. Honore PM, Joannes-Boyau O. High volume hemofiltration (HVHF) in sepsis: A comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs 2004; 27: 1077-82.
12. Honore PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level - the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004; 32: 896-7.
13. Kashiwazaki M, Tanaka T, Kanda H, et al. A high endothelial venule-expressing promiscuous chemokine receptor DARC can bind inflammatory, but not lymphoid, chemokines and is dispensable for lymphocyte homing under physiological conditions. Int Immunol 2003; 15: 1219-27.
14. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173: 6418-26.
15. Sair M, Etherington PJ, Peter Winlove C, Evans TW. Tissue oxygenation and perfusion in patients with systemic sepsis. Crit Care Med 2001; 29: 1343-9.
16. Castell JV, Geiger T, Gross V, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988; 177: 357-61.
17. Parker JC, Rippe B, Taylor AE. Fluid filtration and protein clearances through large and small pore populations in dog lung capillaries. Microvasc Res 1986; 31: 1-17.
18. Kimura G, Irie A, Kuroda K, Kojima S, Satani M. Absence of transcellular fluid shift during haemofiltration. Proc Eur Dial Transplant Assoc 1980; 17: 192-6.
19. Henriksen JH, Parving HH, Lassen NA, Winkler K. Increased transvascular escape rate and lymph drainage of albumin in pigs during intravenous diuretic medication. Relations to treatment in man and transport mechanisms. Scand J Clin Lab Invest 1982; 42: 423-9.
20. Wallace JR, Bell DR. Comparison of protein lymph flux and extravascular uptake in skin during increased venous pressure. Am J Physiol 1992; 263: H895-902.
21. Gandhi RR, Bell DR. Influence of saline infusions on transvascular protein transport. Am J Physiol 1992; 262: H443-50.
22. Wasserman K, Mayerson HS. Mechanism of plasma protein changes following saline infusions. Am J Physiol 1952; 170: 1-10.
23. Wasserman K, Mayerson HS. Dynamics of lymph and plasma protein exchange. Cardiologia 1952; 21: 296-307.
24. Smeby LC, Charlton B, Schindhelm K. Kinetics of intravenous saline infusion and selective IgG removal in rabbits. Am J Physiol 1984; 247:R816-26.
25. Charlton B, Schindhelm K, Smeby LC, Farrell PC. Analysis of immunoglobulin G kinetics in the non-steady state. J Lab Clin Med 1985; 105: 312-20.
26. Onarheim H, Missavage AE, Gunther RA, Kramer GC, Reed RK, Laurent TC. Marked increase of plasma hyaluronan after major thermal injury and infusion therapy. J Surg Res 1991; 50: 259-65.
27. Olszewski WL. The lymphatic system in body homeostasis: Physiological conditions. Lymphat Res Biol 2003; 1: 11-21.
28. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997; 23: 878-84.
29. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002; 21: 25-9.
30. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-8.
31. Hallgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 682-7.
32. Liu N. Metabolism of macromolecules in tissue. Lymphat Res Biol 2003; 1: 67-70.
33. Berg S, Golster M, Lisander B. Albumin extravasation and tissue washout of hyaluronan after plasma volume expansion with crystalloid or hypooncotic colloid solutions. Acta Anaesthesiol Scand 2002; 46: 166-72.
34. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J Immunol 1985; 135: 3972-7.
35. Capper SJ, Kalinka S, Mander TH. Specific radio-immunoassays for IL 1 alpha and IL 1 beta in plasma at physiological and acidic pH: Determination of immunoreactive forms by gel filtration and radioligand binding studies. Cytokine 1990; 2: 182-9.
36. Newton RC, Uhl J, Covington M, Back O. The distribution and clearance of radiolabeled human interleukin-1 beta in mice. Lymphokine Res 1988; 7: 207-16.
37. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res 1982; 2: 301-8.
38. Ferraiolo BL, Fuller GB, Burnett B, Chan E. Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration. J Biol Response Mod 1988; 7: 115-22.
39. Crawford JH, Yang S, Zhou M, Simms HH, Wang P. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med 2004; 32: 502-8.
40. Deaciuc IV, Alappat JM, McDonough KH, D'Souza NB. Effect of chronic alcohol consumption by rats on tumor necrosis factor-alpha and interleukin-6 clearance in vivo and by the isolated, perfused liver. Biochem Pharmacol 1996; 52: 891-9.
41. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005; 288: L3-L15.
42. Dawson TC, Lentsch AB, Wang Z, et al. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 2000; 96: 1681-4.
43. Svensen CH, Brauer KP, Hahn RG, et al. Elimination rate constant describing clearance of infused fluid from plasma is independent of large infusion volumes of 0.9% saline in sheep. Anesthesiology 2004; 101: 666-74.
44. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000; 356: 26-30.
45. Stahle L, Nilsson A, Hahn RG. Modelling the volume of expandable body fluid spaces during i.v. fluid therapy. Br J Anaesth 1997; 78: 138-43.
46. Kellen MR, Bassingthwaighte JB. An integrative model of coupled water and solute exchange in the heart. Am J Physiol Heart Circ Physiol 2003; 285: H1303-16.
47. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif 1998; 16: 261-8.
48. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome. Ren Fail 1997; 19: 443-54.
49. Honore PM, Matson JR. Hemofiltration, adsorption, sieving and the challenge of sepsis therapy design. Crit Care 2002; 6: 394-6.
50. Kandus A, Ponikvar R, Drinovec J, Pavlin K, Ivanovich P. Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters. Int J Artif Organs 1990; 13: 200-4.
51. Uchino S, Cole L, Morimatsu H, Goldsmith D, Ronco C, Bellomo R. Solute mass balance during isovolaemic high volume haemofiltration. Intensive Care Med 2003; 29: 1541-6.
52. Choi G, Gomersall CD, Lipman J, et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents 2004; 24: 468-72.
53. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004; 58: 259-68.
54. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003; 49: 280-6.
55. Bolon M, Bastien O, Flamens C, Paulus S, Boulieu R. Midazolam disposition in patients undergoing continuous venovenous hemodialysis. J Clin Pharmacol 2001; 41: 959-62.
56. Townsley MI, Reed RK, Ishibashi M, Parker JC, Laurent TC, Taylor AE. Hyaluronan efflux from canine lung with increased hydrostatic pressure and saline loading. Am J Respir Crit Care Med 1994; 150: 1605-11.